Inovio Pharmaceuticals Launches Public Stock Offering
Plymouth Meeting-based Inovio Pharmaceuticals announced plans for an underwritten public offering of common stock and accompanying warrants. The biotechnology firm, which focuses on DNA-based therapies for cancer and infectious diseases, intends to grant underwriters a 30-day option to purchase an additional 15% of the offered securities.
Piper Sandler will serve as the sole manager for the transaction. The offering follows a shelf registration statement that was declared effective by the Securities and Exchange Commission on July 10, 2026. While the company has moved forward with the proposal, the final size and specific terms remain subject to market conditions and regulatory finalization.
Inovio plans to utilize the formal prospectus process for the distribution of shares, with materials made available through the SEC website and the lead underwriter. The company cautioned that the completion of the offering is not guaranteed and depends on prevailing financial conditions. All securities involved in this capital raise will be sold directly by the firm.
Comments (0)
No comments yet. Be the first!